{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:40:47Z","timestamp":1761129647960},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.sxmr.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T22:04:58Z","timestamp":1560204298000},"page":"690-698","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Discontinuation from Collagenase Clostridium histolyticum Therapy for Peyronie\u2019s Disease: Review and Single-Center Cohort Analysis"],"prefix":"10.1093","volume":"7","author":[{"given":"Arash","family":"Amighi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriram V.","family":"Eleswarapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Mendhiratta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin J.","family":"Nork","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse N.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2019.05.001_bib1","first-page":"199","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/andr.12058","article-title":"Therapeutic advances in the treatment of Peyronie's disease","volume":"3","author":"Yafi","year":"2015","journal-title":"Andrology"},{"key":"10.1016\/j.sxmr.2019.05.001_bib3","first-page":"397","article-title":"Medical management of Peyronie's disease","volume":"30","author":"Hellstrom","year":"2009","journal-title":"J\u00a0Androl"},{"key":"10.1016\/j.sxmr.2019.05.001_bib4","first-page":"1051","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/PPA.S113507","article-title":"Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: Patient selection and perspectives","volume":"11","author":"Kuhlmann","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.sxmr.2019.05.001_bib6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1756287216637569","article-title":"Collagenase Clostridium histolyticum in the management of Peyronie's disease: A review of the evidence","volume":"8","author":"Traore","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib7","first-page":"2268","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.13120","article-title":"Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD)","volume":"116","author":"Carson","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.05.001_bib9","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s40265-016-0649-1","article-title":"Collagenase Clostridium histolyticum for the treatment of Peyronie's disease: A \u201creal world\u201d clinical perspective","volume":"76","author":"Anaissie","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.sxmr.2019.05.001_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41585-018-0117-7","article-title":"Nonsurgical management of Peyronie's disease","volume":"16","author":"Tsambarlis","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.23736\/S0393-2249.18.03118-1","article-title":"Collagenase Clostridium histolyticum: A novel medical treatment for Peyronie's disease","volume":"70","author":"Abdel Raheem","year":"2018","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1756287218755020","article-title":"Intralesional collagenase Clostridium histolyticum in the management of Peyronie's disease: Current best practice","volume":"10","author":"Cwikla","year":"2018","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5534\/wjmh.17033","article-title":"Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: Review of a minimally invasive treatment option","volume":"35","author":"Gabrielson","year":"2017","journal-title":"World J Mens Health"},{"key":"10.1016\/j.sxmr.2019.05.001_bib14","first-page":"1430","article-title":"Treatment of Peyronie's disease with collagenase Clostridium histolyticum and vacuum therapy: A randomized, open-label pilot study","volume":"14","author":"Ralph","year":"2017","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.05.001_bib15","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.esxm.2017.02.001","article-title":"Changes in the effects of Peyronie's disease after treatment with collagenase Clostridium histolyticum: Male patients and their female partners","volume":"5","author":"Goldstein","year":"2017","journal-title":"Sex Med"},{"key":"10.1016\/j.sxmr.2019.05.001_bib16","first-page":"248","article-title":"Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie's disease: A phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.05.001_bib17","first-page":"1220","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie's disease","volume":"14","author":"Nguyen","year":"2017","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.05.001_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease","volume":"104","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.05.001_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","article-title":"Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.05.001_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie's disease and injectable collagenase Clostridium histolyticum: Safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.05.001_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2017.04.045","article-title":"Self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase Clostridium histolyticum injections for Peyronie disease","volume":"106","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.05.001_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41443-018-0063-1","article-title":"Limited success with clostridium Collagenase histolyticum following FDA approval for the treatment of Peyronie's disease","volume":"31","author":"Tsambarlis","year":"2019","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.05.001_bib23","first-page":"777","article-title":"Intralesional collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie's disease: Results of a multi-institutional analysis","volume":"201","author":"Hellstrom","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.21037\/tau.2017.07.26","article-title":"Racial variations in response to intralesional collagenase Clostridium histolyticum in men with Peyronie's disease","volume":"6","author":"Nguyen","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.sxmr.2019.05.001_bib25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.sxmr.2017.07.011","article-title":"Intralesional injection of collagenase Clostridium histolyticum may increase the risk of late-onset penile fracture","volume":"6","author":"Beilan","year":"2018","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2019.05.001_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: An important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie's disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.05.001_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.urpr.2016.04.005","article-title":"Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie\u2019s disease deformities","volume":"4","author":"Cordon","year":"2017","journal-title":"Urol Pract"},{"key":"10.1016\/j.sxmr.2019.05.001_bib28","first-page":"259","article-title":"Surgical correction of persistent Peyronie's disease following collagenase Clostridium histolyticum treatment","volume":"12","author":"Levine","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.05.001_bib29","first-page":"684","article-title":"Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for Peyronie's disease","volume":"13","author":"Yafi","year":"2016","journal-title":"J\u00a0Sex Med"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205005211930040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205005211930040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:37:30Z","timestamp":1672774650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205005211930040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S205005211930040X"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2019.05.001","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation from Collagenase Clostridium histolyticum Therapy for Peyronie\u2019s Disease: Review and Single-Center Cohort Analysis","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}